Pfizer EPS from Continuing Operations decreased by 24.2% to $0.47 in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 9.6%, from $0.52 to $0.47. Over 2 years (FY 2021 to FY 2024), EPS from Continuing Operations shows a downward trend with a -39.9% CAGR.
c_eps_continuing_operations| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.02 | $1.43 | $0.62 | $1.37 | $1.73 | $1.51 | $0.87 | $0.97 | $0.41 | -$0.42 | $0.55 | $0.01 | $0.79 | $0.07 | $0.52 | $0.51 | $0.62 | $0.47 |
| QoQ Change | — | +40.2% | -56.6% | +121.0% | +26.3% | -12.7% | -42.4% | +11.5% | -57.7% | -202.4% | +231.0% | -98.2% | >999% | -91.1% | +642.9% | -1.9% | +21.6% | -24.2% |
| YoY Change | — | — | — | — | +69.6% | +5.6% | +40.3% | -29.2% | -76.3% | -127.8% | -43.3% | -97.6% | +288.1% | — | -5.5% | >999% | -21.5% | -9.6% |